

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



November 14, 2025

Company name: FUKUVI CHEMICAL INDUSTRY CO.,LTD
Listing: Tokyo Stock Exchange, Nagoya Stock Exchange
Securities code: 7871
Name of representative: Katsunori Mori, President,
Chief Operating Officer
Inquiries: Naoki Kashiwa, General Manager, Corporate
Communications and Investor Relations Office

(Corrections / Corrections of Numerical Data) Summary of Consolidated Financial Results for the Three Months Ended June 30, 2025[Japanese GAAP]

FUKUVI CHEMICAL INDUSTRY CO.,LTD (“the Company”) announces the corrections to the “Summary of Consolidated Financial Results for the Three Months Ended June 30, 2025[Japanese GAAP]” released on August 8, 2025. As numerical data has also been corrected, the corrected numerical data is also sent.

1. Reason for Corrections

After the release of the " Summary of Consolidated Financial Results for the Three Months Ended June 30, 2025[Japanese GAAP]", it was found that the corrections were necessary due to errors in the quarterly consolidated balance sheet and related disclosures. Therefore, the Company is issuing this correction.

2. Details of Corrections

The corrections are indicated with underlines.

○Summary

1. Consolidated financial results for the three months ended June 30, 2025 (from April 1, 2025 to June 30, 2025)

(2) Consolidated financial position

[Before corrections]

	Total assets	Net assets	Capital adequacy ratio
As of	Millions of yen	Millions of yen	%
June 30, 2025	53,184	37,266	68.9
March 31, 2025	53,237	37,520	68.7

(Reference) Equity: As of June 30, 2025: ¥ 36,651 million
As of March 31, 2025: ¥ 36,595 million

[After corrections]

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
June 30, 2025	53,184	37,266	68.9
March 31, 2025	53,237	37,520	68.7

Reference: Equity
As of June 30, 2025: ¥ 36,645 million
As of March 31, 2025: ¥ 36,595 million

Quarterly Consolidated Financial Statements and Primary Notes

Quarterly Consolidated Balance Sheet

[Before corrections]

(Millions of yen)

	As of March 31, 2025	As of June 30, 2025
Liabilities		
Current liabilities		
Notes and accounts payable - trade	5,568	4,721
Short-term borrowings	82	80
Current portion of long-term borrowings	17	17
Electronically recorded obligations - operating	3,931	4,725
Income taxes payable	388	246
Accrued expenses	1,124	1,097
Lease liabilities	322	330
Liabilities related to charged supply	504	507
Provision for bonuses	683	953
Provision for bonuses for directors (and other officers)	14	18
Provision for product compensation	47	35
Other provisions	29	6
Other	684	892
Total current liabilities	13,394	13,625
Non-current liabilities		
Long-term borrowings	33	33
Lease liabilities	624	630
Deferred tax liabilities	1,308	1,274
Retirement benefit liability	68	64
Other	291	291
Total non-current liabilities	2,323	2,293
Total liabilities	15,717	15,918
Net assets		
Shareholders' equity		
Share capital	2,194	2,194
Capital surplus	1,511	1,533
Retained earnings	30,465	30,491
Treasury shares	(598)	(598)
Total shareholders' equity	33,572	33,620
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2,113	2,227
Foreign currency translation adjustment	469	383
Remeasurements of defined benefit plans	441	421
Total accumulated other comprehensive income	3,023	3,031
Non-controlling interests	924	615
Total net assets	37,520	37,266
Total liabilities and net assets	53,237	53,184

[After corrections]

(Millions of yen)

	As of March 31, 2025	As of June 30, 2025
Liabilities		
Current liabilities		
Notes and accounts payable - trade	5,568	4,721
Short-term borrowings	82	80
Current portion of long-term borrowings	17	17
Electronically recorded obligations - operating	3,931	4,725
Income taxes payable	388	246
Accrued expenses	1,124	1,097
Lease liabilities	322	330
Liabilities related to charged supply	504	507
Provision for bonuses	683	953
Provision for bonuses for directors (and other officers)	14	18
Provision for product compensation	47	35
Other provisions	29	6
Other	684	892
Total current liabilities	13,394	13,625
Non-current liabilities		
Long-term borrowings	33	33
Lease liabilities	624	630
Deferred tax liabilities	1,308	1,274
Retirement benefit liability	68	64
Other	291	291
Total non-current liabilities	2,323	2,293
Total liabilities	15,717	15,918
Net assets		
Shareholders' equity		
Share capital	2,194	2,194
Capital surplus	1,511	1,527
Retained earnings	30,465	30,491
Treasury shares	(598)	(598)
Total shareholders' equity	33,572	33,614
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2,113	2,227
Foreign currency translation adjustment	469	383
Remeasurements of defined benefit plans	441	421
Total accumulated other comprehensive income	3,023	3,031
Non-controlling interests	924	621
Total net assets	37,520	37,266
Total liabilities and net assets	53,237	53,184